<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">NEYNS, BART</style></author><author><style face="normal" font="default" size="100%">VAN NIEUWENHOVE, YVES</style></author><author><style face="normal" font="default" size="100%">AERTS, MARIDI</style></author><author><style face="normal" font="default" size="100%">FONTAINE, CHRISTEL</style></author><author><style face="normal" font="default" size="100%">VERMEIJ, JOANNA</style></author><author><style face="normal" font="default" size="100%">SCHALLIER, DENNIS</style></author><author><style face="normal" font="default" size="100%">DECOSTER, LORE</style></author><author><style face="normal" font="default" size="100%">DE MEY, JOHAN</style></author><author><style face="normal" font="default" size="100%">VANDENBROUCKE, FREDERIK</style></author><author><style face="normal" font="default" size="100%">HOORENS, ANNE</style></author><author><style face="normal" font="default" size="100%">DELVAUX, GEORGES</style></author><author><style face="normal" font="default" size="100%">DE GRÉVE, JACQUES</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Hepatic Arterial Infusion of Oxaliplatin and L-Folinic Acid-modulated 5-Fluorouracil for Colorectal Cancer Liver Metastases</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2006</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2006-01-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">611-619</style></pages><volume><style face="normal" font="default" size="100%">26</style></volume><issue><style face="normal" font="default" size="100%">1B</style></issue><abstract><style  face="normal" font="default" size="100%">Background: Despite the progress made in the treatment of metastatic colorectal cancer (CRC), the results of second-line chemotherapy remain poor. Patients and Methods: The feasibility of hepatic arterial infusion (HAI) of oxaliplatin (100 mg/m2 over 6 h) followed by l-folinic acid (L-FA) (400 mg over 2 h i.v.)-modulated continuous HAI of 5-Fluorouracil (5-FU) (60 mg/kg over 42 h; q2w) as second-line chemotherapy for metastatic CRC limited to the liver was investigated. Results: A median of 9 treatment cycles were administered (range 4-14). Treatment-limiting toxicity consisted of: abdominal pain (3 patients), elevated liver enzymes accompanied by fatigue (3), elevated bilirubin (2), neutropenia (2), thrombocytopenia (3) and hypersensitivity to oxaliplatin (1). Normalization for &gt;4 weeks of the carcinoembryonic antigen (CEA) level was documented in 3 patients and a decline of &gt;50% for &gt;4 weeks in 5 patients. A confirmed partial response (PR) was documented in 5, stable disease (SD) in 1 and progressive disease (PD) in 3 patients. In the latter 3 patients, lung metastases developed while a PR was observed in the liver metastases. A pathological complete response (CR) was documented in 2 patients. The median time to progression was 7.2 months (95% CI 1.3-13) and the median overall survival 18.3 months (95% CI 16.3-20.3). Conclusion: HAI of oxaliplatin plus CI5-FU/LV is feasible and merits further evaluation. Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved</style></abstract></record></records></xml>